The Crosswalk

    NewPer-page social previews and this changelog

    FDA Philippines

    Flag of PhilippinesPhilippines - FDA Philippines

    GuidanceLast updated · 2023Verified · 2026-07-16

    AO 2018-0002 + FDA Circulars on SaMD and cybersecurity

    Share

    Authority

    Food and Drug Administration, Philippines, Center for Device Regulation, Radiation Health and Research

    Enforced

    2018

    Legal framework

    RA 9711 (FDA Act) + AO 2018-0002 + Data Privacy Act 2012

    FDA package reuse

    ~80%

    Scope

    All medical devices marketed in the Philippines; SaMD scope expanding via FDA Circulars.

    Pre-market

    Risk-class registration; ASEAN CSDT template; FDA / CE accepted.

    Post-market

    Adverse-event reporting; National Privacy Commission breach notifications.

    SBOM

    Recommended

    Encouraged for SaMD; not yet mandated.

    Vulnerability disclosure

    DICT-CERT coordinated disclosure recommended.

    Penalty

    Registration cancellation; Data Privacy Act fines and criminal liability.

    Unique requirements

    • 01Philippine License to Operate (LTO)
    • 02Philippine Authorised Representative
    • 03Filipino / English IFU and labelling

    Highlights

    • ASEAN CSDT template alignment
    • Data Privacy Act overlay
    • FDA / CE approvals accepted

    Aligns with

    ASEAN MDD IMDRF N60 ISO 13485

    Timeline

    1. 2018

      AO 2018-0002 published

    2. 2023

      SaMD and cyber circulars expanded

    Key documents

    How to submit in Philippines

    Playbook reviewed · 2026-07-16

    Submission route

    Philippine FDA Certificate of Product Registration (CPR)

    Philippine FDA operates a CPR route with heavy reliance on GHTF founding-member approvals for higher-risk devices.

    Authority portal

    Step-by-step

    1. Step 01

      Appoint local representation

      Most jurisdictions require a locally-established entity to hold the registration or act as authorised representative before submission.

    2. Step 02

      Reuse FDA or CE package as baseline

      Adapt the cybersecurity subsection you already prepared for FDA or CE; regulators here typically accept the structure and ask for local labeling additions.

    3. Step 03

      Translate and localise

      Local-language technical summary and labeling are usually mandatory; certified translation is safest.

    4. Step 04

      Submit + track queries

      Respond to clarification rounds promptly; each unanswered question can add 30-90 days to the clock.

    Evidence checklist

    Item Level FDA equivalent Notes
    Cybersecurity documentation (baseline FDA or CE) Required SPDF
    Local authorised representative agreement Required
    Local-language labeling and IFU Required
    SBOM Recommended Not mandatory but reduces clarification rounds.

    Common FDA-PH rejections

    No Licence to Operate (LTO) for local importer

    Common

    Fix · Ensure importer holds a valid LTO before filing.

    Typical timeline

    End-to-end window: 4-9 months

    Phase 01

    Local rep + dossier prep

    2-4 months

    Phase 02

    Regulatory review

    4-9 months

    Phase 03

    Approval + market entry

    1-3 months

    Related markets

    Frequently asked about Philippines

    Is SBOM required for medical devices in Philippines?

    Recommended. Encouraged for SaMD; not yet mandated.

    What does FDA Philippines require for pre-market cybersecurity?

    Risk-class registration; ASEAN CSDT template; FDA / CE accepted.

    What are the post-market cybersecurity obligations under FDA Philippines?

    Adverse-event reporting; National Privacy Commission breach notifications.

    What is the penalty for non-compliance with FDA Philippines cybersecurity rules?

    Registration cancellation; Data Privacy Act fines and criminal liability.

    How much of my FDA cybersecurity package is reusable in Philippines?

    Roughly 80% - an editorial estimate based on overlapping evidence requirements (threat model, SBOM, security risk assessment, pen-test report).